Skip to content

Corona Debrief: Drosten and Vaccine Mandate

  • News

Christian Drosten, a renowned German virologist, played a central role in public perception and policy advice during the Corona pandemic[3]. As head of virology at Charité Berlin and co-developer of the first PCR test for SARS-CoV-2, he became one of the most important voices in pandemic control[3]. Drosten already warned in 2017 about the potential of the SARS virus and was instrumental in the early diagnosis of COVID-19[3]. His expertise led him to serve as an advisor to federal and state governments and to frequently appear in the media as the "nation's Corona explainer"[3]. Regarding the COVID-19 vaccination campaign, Drosten held a clear pro-vaccination stance. He repeatedly emphasized the importance of vaccinations in curbing the pandemic[4]. However, Drosten himself had no direct decision-making power over a possible vaccine mandate, as this was ultimately a political decision. The effectiveness of COVID-19 vaccines has been proven by numerous studies. According to the Robert Koch Institute… 

more »Corona Debrief: Drosten and Vaccine Mandate

First AI-powered pipeline for personalized cancer vaccines

  • News

Scientists at Ludwig Cancer Research have developed a complete drug pipeline that integrates multiple molecular and genetic analyses of tumors and the specific molecular targets of T cells, using artificial intelligence algorithms to enable personalized cancer vaccines for patients with their results. The design, validation, and comparative evaluation of this computer suite, NeoDisc, are described in detail in the current issue of Nature Biotechnology in a publication led by Florian Huber and Michal Bassani-Sternberg of the Lausanne branch of the Ludwig Institute for Cancer Research. "NeoDisc offers unique insights into the immunobiology of tumors and the mechanisms by which they evade the attack surface for cytotoxic T cells of the immune system," said Bassani-Sternberg. "These insights are invaluable for the development of personalized immunotherapies, and the analytical and computational pipeline that forms the core of NeoDisc is already being used here in Lausanne...

more »First AI-powered pipeline for personalized cancer vaccines

Nanoparticles combat obesity

  • News

Researchers have presented a novel approach to combating obesity that targets fat absorption in the small intestine. The cutting-edge nanoparticle system, designed to deliver therapeutic molecules directly to the digestive tract, has shown significant potential in preventing diet-induced obesity. The study, presented yesterday at UEG Week 2024, focuses on an enzyme called sterol O-acyltransferase 2 (SOAT2), which plays a crucial role in fat absorption in the small intestine.3,4 By inhibiting this enzyme in the small intestine, the study offers a promising therapeutic approach to reducing fat absorption and potentially preventing obesity. Despite extensive research into fat metabolism, effective inhibitors of intestinal fatty acid absorption have not yet emerged. "For years, researchers have been studying fat metabolism, but it has been difficult to find an effective way to block fat absorption," explained lead researcher Dr. Wentao Shao. "While...

more »Nanoparticles combat obesity

Life Sciences: Events to watch

For the period from October 14 to 31, 2024, the following important dates in biotech and medicine should be noted: The PSP Conference 2024, with a focus on health, will take place on October 14 and 15 at the Fraunhofer Conference Center in Potsdam Science Park[1]. This two-day event offers an exciting program with the latest research findings, product innovations, and impulses from the Berlin-Brandenburg capital region. Topics such as personalized medicine, artificial intelligence in medicine, and (digital) diagnostics are the focus[1]. On October 14, 2024, XChange 2024 will take place in Munich, addressing the topic of Artificial Intelligence in Radiation Therapy[2]. This event offers experts the opportunity to exchange ideas about the latest developments in this field. The Biointelligence Congress is planned for October 22, 2024, in Stuttgart[1]. This event brings together professionals from various fields of biotechnology and bioinformatics to discuss innovative approaches and technologies… 

more »Life Sciences: Events to watch

Mavacamten  Improves Cardiac Biomarkers in HFpEF Patients

Mavacamten, a drug originally developed to treat hypertrophic cardiomyopathy, has shown signs of reducing cardiac strain in patients with heart failure with preserved ejection fraction. Heart failure with preserved ejection fraction (HFpEF) affects nearly half of all heart failure patients. It is characterized by the heart's inability to fill with blood adequately, despite normal pumping function. Patients with a left ventricular ejection fraction (LVEF) of 60% or higher constitute 43% to 46% of HFpEF patients. These individuals often respond less favorably to standard heart failure treatments, limiting effective therapeutic options. Mavacamten is a cardiac myosin inhibitor already approved for treating hypertrophic cardiomyopathy (HCM), demonstrating its ability to lower certain biomarkers in non-obstructive HCM cases. Researchers hypothesized that similar mechanisms could benefit HFpEF patients by improving cardiac muscle relaxation and… 

more »Mavacamten  Improves Cardiac Biomarkers in HFpEF Patients

Children: Early sleepers have greater microbial diversity in gut flora

Researchers from the Department of Pediatric Rehabilitation in China have found significant differences in the gut flora of children who go to bed early compared to those who stay up late. The study found that children with earlier bedtimes had greater microbial diversity in their gut flora. Previous studies have shown that adequate sleep improves academic performance and physical growth and is associated with a healthier BMI. The current study examined the relationship between children's sleep behavior and their gut flora. Genomic analysis revealed that children who went to bed early had higher levels of certain beneficial gut bacteria. In particular, Akkermansia muciniphila was significantly more prevalent in the group that went to bed early. Other elevated bacterial levels in early sleepers included Holdemania filiformis, Firmicutes bacterium CAG-95, Streptococcus sp. A12, Weissella confusa, Clostridium sp. CAG-253, Alistipes finegoldii, and Eubacterium siraeum. Additionally, levels of...

more »Children: Early sleepers have greater microbial diversity in their gut flora

Semaglutide and ReCET Reduce Need for Insulin Therapy in Diabetes

  • News

A groundbreaking study presented at UEG Week 2024 investigates a novel treatment strategy for type 2 diabetes (T2D) that has the potential to significantly reduce or even eliminate the need for insulin therapy[1]. This innovative approach combines a novel procedure called ReCET (Re-Cellularization via Electroporation Therapy) with the drug semaglutide. ReCET is a procedure performed under deep sedation that aims to improve the body's sensitivity to its own insulin[1]. Following the ReCET treatment, study participants followed a two-week isocaloric liquid diet before gradually starting semaglutide, up to a dose of 1mg per week[1]. Semaglutide is a drug in the GLP-1 receptor agonist class used to treat type 2 diabetes and as a weight-loss agent[3]. It works by increasing insulin secretion, lowering glucagon release, delaying gastric emptying, and reducing appetite[4]. The… 

more »Semaglutide and ReCET Reduce Need for Insulin Therapy in Diabetes

ReCET with semaglutide may eliminate insulin dependency in type 2 diabetes

Groundbreaking research presented today at UEG Week 2024 reveals a promising new treatment strategy for type 2 diabetes (T2D) that could significantly reduce or even eliminate the need for insulin therapy. This innovative approach, which combines a novel procedure known as ReCET (Re-Cellularization via Electroporation Therapy) with semaglutide, resulted in the elimination of insulin therapy for 86% of patients. Globally, T2D affects 422 million people, with obesity recognised as a significant risk factor. While insulin therapy is commonly used to manage blood sugar levels in T2D patients, it can result in side effects such as weight gain and further complicate diabetes management. A need therefore exists for alternative treatment strategies. The first-in-human study included 14 participants aged 28 to 75 years, with body mass indices ranging from 24 to 40 kg/m². Each participant underwent the ReCET procedure under deep sedation,… 

more »ReCET with semaglutide may eliminate insulin dependency in type 2 diabetes

Canton of Zurich and Foundations Deepen Cooperation

The Office for Economic Affairs of the Canton of Zurich and the SwissFoundations association held their second foundation discussion. The focus was on the optimal design of cooperation. Common goals and the earliest possible exchange were identified as decisive.     The Office for Economic Affairs of the Canton of Zurich and the SwissFoundations association met on October 1st at Kraftwerk/Impact […] Canton of Zurich and Foundations deepen cooperation

ETH remains one of the world's best universities

Die Eidgenössische Technische Hochschule Zürich (ETH) belegt den elften Platz im neuesten Hochschul-Ranking von Times Higher Education (THE). Auf Platz eins steht die Universität Oxford. Die Eidgenössische Technische Hochschule Lausanne landet auf Platz 32, die Universität Zürich auf dem 80. Rang.     Die Eidgenössische Technische Hochschule Zürich (ETH) belegt laut einer Medienmitteilung zum dritten Mal in […] ETH bleibt eine der weltweit besten Universitäten